{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.06","upperLimit":"100","value":"60"},{"groupId":"OG001","lowerLimit":"13.32","upperLimit":"100","value":"66.67"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"86.68","value":"33.33"},{"groupId":"OG003","lowerLimit":"53.78","upperLimit":"96.22","value":"75"},{"groupId":"OG004","lowerLimit":"11.56","upperLimit":"55.11","value":"33.33"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Pediatric Patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.56","upperLimit":"100","value":"75"},{"groupId":"OG001","lowerLimit":"28.95","upperLimit":"100","value":"66.67"},{"groupId":"OG002","lowerLimit":"20.48","upperLimit":"93.80","value":"57.14"},{"groupId":"OG003","lowerLimit":"74.50","upperLimit":"98.83","value":"86.67"},{"groupId":"OG004","lowerLimit":"17.18","upperLimit":"54.82","value":"36"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"82.94","value":"40"},{"groupId":"OG006","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"title":"Adult Patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"Participants who experienced Grade 3 or higher toxicity was assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose-Finding Level 1 CR:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG000","title":"Dose-Finding Level 1 CR"},{"description":"Dose-Finding Level 1 RT:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG001","title":"Dose-Finding Level 1 RT"},{"description":"Dose-Finding Level 2 RT:\n\nAdult: Pazopanib 800 mg; Pediatric:\n\nPazopanib 450 mg/m2","id":"OG002","title":"Dose-Finding Level 2 RT"},{"description":"Regimen A: Chemoradiation plus pazopanib","id":"OG003","title":"Regimen A"},{"description":"Regimen B: Chemoradiation alone","id":"OG004","title":"Regimen B"},{"description":"Regimen C: Radiation therapy plus pazopanib","id":"OG005","title":"Regimen C"},{"description":"Regimen D: Radiation therapy alone","id":"OG006","title":"Regimen D"}],"paramType":"NUMBER","populationDescription":"Ineligible patients are excluded.","reportingStatus":"POSTED","timeFrame":"Reporting of adverse events was required from the start of protocol therapy and until 30 days from the last administration of study drugs; up to 1 year","title":"Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}